T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients.

Trial Profile

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 27 Sep 2012

At a glance

  • Drugs Batabulin (Primary) ; Doxorubicin
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Tularik
  • Most Recent Events

    • 27 Sep 2012 New trial record
    • 27 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top